A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 409 participants.

Also called NCT06660173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 409 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06660173
  • EU CT 2024-513539-25-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, Greece, Hong Kong SAR China, Hungary, Italy, Japan, Poland, Puerto Rico, Romania, South Korea, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06660173. Randomized; double masking; primary purpose treatment. Start 2024-11-07 (actual); primary completion 2025-10-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Maridebart Cafraglutide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct06660173
Content hash
ed220e20262b92ffd02491a4a0e77804f0d5392cee1372b3c42cc0b5461def99